Beijing Strong Biotechnologies,Inc. (SHE:300406)
China · Delayed Price · Currency is CNY 11.71
+0.31 (2.72%)
Sep 21, 2026, 3:04 PM CST
SHE:300406 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
| 6,848 | 7,643 | 7,797 | 11,206 | 9,611 | 11,674 | |
Market Cap Growth | -12.77% | -1.98% | -30.42% | 16.60% | -17.67% | -20.79% |
Enterprise Value | 7,138 | 7,960 | 7,968 | 11,921 | 10,422 | 12,416 |
Last Close Price | 11.71 | 12.18 | 11.66 | 16.50 | 14.08 | 16.94 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
PE Ratio | 30.89 | 40.25 | 14.49 | 21.40 | 24.70 | 28.78 |
Forward PE | 16.49 | 13.07 | 10.80 | 18.21 | 18.45 | 21.43 |
PS Ratio | 5.01 | 5.64 | 4.70 | 6.43 | 6.36 | 7.30 |
PB Ratio | 1.91 | 2.02 | 1.89 | 3.01 | 2.94 | 4.01 |
P/TBV Ratio | 3.36 | 3.42 | 3.26 | 5.63 | 6.27 | 10.35 |
P/FCF Ratio | 12.65 | 14.53 | 14.27 | 25.64 | 32.07 | 42.31 |
P/OCF Ratio | 12.06 | 13.53 | 12.70 | 19.15 | 24.26 | 34.22 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.23 | 5.87 | 4.80 | 6.85 | 6.90 | 7.76 |
EV/EBITDA Ratio | 12.73 | 15.79 | 11.36 | 18.12 | 18.80 | 21.03 |
EV/EBIT Ratio | 14.49 | 18.25 | 12.61 | 19.73 | 20.79 | 22.65 |
EV/FCF Ratio | 13.19 | 15.14 | 14.58 | 27.28 | 34.78 | 45.00 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.30 | 0.28 | 0.28 | 0.31 | 0.34 | 0.39 |
Debt / EBITDA Ratio | 1.94 | 2.13 | 1.66 | 1.72 | 1.98 | 1.90 |
Debt / FCF Ratio | 2.01 | 2.05 | 2.14 | 2.60 | 3.68 | 4.08 |
Net Debt / Equity Ratio | 0.08 | 0.06 | 0.01 | 0.07 | 0.13 | 0.25 |
Net Debt / EBITDA Ratio | 0.53 | 0.43 | 0.05 | 0.39 | 0.79 | 1.24 |
Net Debt / FCF Ratio | 0.55 | 0.41 | 0.07 | 0.59 | 1.46 | 2.65 |
Asset Turnover | 0.27 | 0.26 | 0.31 | 0.36 | 0.34 | 0.39 |
Inventory Turnover | 1.33 | 1.40 | 1.61 | 1.98 | 1.63 | 1.80 |
Quick Ratio | 10.56 | 11.28 | 8.31 | 7.01 | 6.01 | 2.38 |
Current Ratio | 11.85 | 12.84 | 9.28 | 7.86 | 6.94 | 2.87 |
Return on Equity (ROE) | 5.88% | 4.82% | 13.69% | 14.94% | 12.76% | 14.82% |
Return on Assets (ROA) | 5.97% | 5.14% | 7.36% | 7.72% | 7.02% | 8.27% |
Return on Invested Capital (ROIC) | 9.67% | 8.63% | 13.44% | 13.83% | 11.97% | 14.17% |
Return on Capital Employed (ROCE) | 10.50% | 8.90% | 12.00% | 12.40% | 11.60% | 14.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.28% | 2.48% | 6.90% | 4.67% | 4.05% | 3.48% |
FCF Yield | 7.90% | 6.88% | 7.01% | 3.90% | 3.12% | 2.36% |
Dividend Yield | 5.98% | 5.75% | 3.43% | 1.21% | 0.71% | 0.59% |
Payout Ratio | 318.48% | 282.89% | 23.07% | 12.35% | 23.30% | 19.38% |
Buyback Yield / Dilution | 0.94% | 0.79% | -0.49% | 3.00% | -4.37% | -7.25% |
Total Shareholder Return | 6.92% | 6.54% | 2.94% | 4.22% | -3.66% | -6.66% |